Total Funding
35
78
Total FundingGrant raised
Growth Score 35 in past quarter
-29 pts
Heat Score 78 in past quarter
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
81194
Beryl is developing a patented first-in-class small molecule to increase peak bone mass and cure poor bone mineral density.
- Alison Lukacsko: Chief Science Officer and Co-Founder
- Larry Gold: Founder & CEO
About the Company
Beryl Therapeutics goal is to open up a new frontier in bone health based on the revelation that lipids are crucial signaling molecules that play a role in bone mass regulation. Beryl is developing a patented first-in-class small molecule to increase peak bone mass and cure poor bone mineral density caused by disease or natural aging.
Women Founded